NCT03621904 PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
| NCT ID | NCT03621904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Radboud University Medical Center |
| Condition | Endometrial Cancer Stage III |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-10-15 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2022-10-15 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
Eligibility Criteria
Inclusion Criteria: * Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer * All histologic types of endometrial carcinoma * Planned treatment with any type of hormonal therapy * Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy. Exclusion Criteria: * Adjuvant hormonal therapy started following complete resection of endometrial carcinoma * Synchronous use of hormonal therapy for other indications * Endometrial sarcoma or endometrial stroma cell sarcoma
Contact & Investigator
Hanny Pijnenborg, MD PhD
PRINCIPAL INVESTIGATOR
Radboud University Medical Center
Frequently Asked Questions
Who can join the NCT03621904 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 110 Years, studying Endometrial Cancer Stage III. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03621904 currently recruiting?
Yes, NCT03621904 is actively recruiting participants. Contact the research team at Maartje.luijten@radboudumc.nl for enrollment information.
Where is the NCT03621904 trial being conducted?
This trial is being conducted at Nijmegen, Netherlands.
Who is sponsoring the NCT03621904 clinical trial?
NCT03621904 is sponsored by Radboud University Medical Center. The principal investigator is Hanny Pijnenborg, MD PhD at Radboud University Medical Center. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.